Imaging Estrogen Receptor Positive Advanced Breast Cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the use of 4-fluoro-11β-methoxy-16α-[18F]fluoroestradiol (4FMFES) PET imaging to assess estrogen receptor (ER) status in patients with advanced ER+ breast cancer. The study aims to provide a non-invasive, whole-body assessment of ER expression, which can vary between tumor sites and over time. By determining ER status more accurately, the trial seeks to improve treatment decisions for patients with stage 3 or 4 breast cancer. Participants will undergo PET imaging to evaluate the correlation between 4FMFES uptake and ER expression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Advanced breast cancer patients, i.e. stage 3 or 4 diseases.
* Aged 18 or older at the time of breast cancer diagnosis.
* Histopathologic review confirming diagnosis of ER positive breast cancer.
* Male patients, although rare, can participate.
* Patient must have given informed consent.
* ECOG performance status 0-3.
* ER must be positive in at least 10% of tumor cells in either the core biopsy or a therapeutic surgical resection.
* Any HER2-neu status.
* Patient eligible for and willing to receive systemic treatment.

Exclusion Criteria:

* Patients who are pregnant or nursing.
* Patients unable to tolerate PET/CT for 30 minutes.
* Patients taking anti-ER hormone therapy that can pharmacologically blockade estrogen receptors (ex: Tamoxifen, Fulvestrant). Patients can undergo 4FMFES-PET if anti-ER therapy was interrupted at least 8 weeks prior imaging. Aromatase inhibitors and LHRH analogs are not expected to interfere with 4FMFES uptake and are thus permitted to be taken prior and during this study.

Where it's running

• Université deSherbrooke
  Sherbrooke, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Eric E Turcotte, MD — Université de Sherbrooke, Centre de Recherche du CHUS
• Study coordinator: Michel Paquette, PhD
• Email: michel.paquette@usherbrooke.ca
• Phone: 819-346-1110

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pre-surgery hormone therapy to lower positive margins in lobular breast cancer

  This Phase 2 trial tests whether giving endocrine (hormone) therapy before breast-conserving surgery can reduce the chance of cancer at the edges of the removed tissue in postmenopausal people with ER+/HER2- invasive lobular breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07483307

• Adherence to Cell Cycle Inhibitors with Endocrine Therapy in Localized High-Risk ER+ Breast Cancer

  This study checks how well patients with localized ER+ breast cancer stick to a combined endocrine therapy and CDK4/6 inhibitor after surgery.

  Recruiting University Hospital, Grenoble · Grenoble · NCT07443774

• Combining FWD1802 with CDK4/6 inhibitors or everolimus for ER+/HER2- advanced breast cancer

  This trial tests whether adding FWD1802 to CDK4/6 inhibitors or everolimus helps people with ER-positive/HER2-negative unresectable locally advanced or metastatic breast cancer who have progressed on or cannot use standard therapy.

  Recruiting Phase 1/2 Forward Pharmaceuticals Co., Ltd. · Shanghai · NCT07002177

• ctDNA-guided elacestrant for ER+ breast cancer

  This trial will test whether giving elacestrant for one year to people with ER+, stage IIB/III breast cancer who have a positive ctDNA test after finishing endocrine therapy can eliminate hidden cancer and lower the chance of recurrence.

  Recruiting at 6 sites Phase 2 Yale University · New Haven, Connecticut and 6 other locations · NCT06923527

• Re‑irradiating the breast after a second lumpectomy

  This trial will test whether targeted re‑irradiation (IMRT) after a second lumpectomy is safe for people with ER+ / HER2‑ breast cancer who previously received breast radiation.

  Recruiting at 2 sites Baptist Health South Florida · Boca Raton, Florida and 1 other locations · NCT06867484

• Understanding breast cancer response during pre-surgery treatment

  This study is trying to see how breast cancer responds to treatment before surgery by looking at tissue and blood samples from patients to find out what factors might affect their recovery and risk of cancer coming back.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT06681064

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.